Literature DB >> 21273949

A review of economic evaluations of genetic testing services and interventions (2004-2009).

Sandjar Djalalov1, Zahra Musa, Michael Mendelson, Katherine Siminovitch, Jeffrey Hoch.   

Abstract

To review economic evaluations of genetic interventions published between 2004 and 2009 and assess the quality of the identified studies, we searched for economic evaluations of genetic testing and interventions published between 2004 and 2009. Studies that met inclusion criteria were reviewed and their quality then assessed using a validated instrument-the Quality of Health Economic Studies. Of 54 articles identified, 26 met study criteria and were included in the review. These studies span a number of clinical indications, genetic tests, and interventions, but the majority (92%) focuses on genetic interventions for preventive screening and increasing treatment efficacy. The mean quality score for the reviewed studies was 89.8. Comparison of the quality of different study types revealed that cost-utility studies and studies that used a combined decision tree and Markov model had the highest mean quality scores. Clear statements regarding bias, funding source, and study perspective were commonly lacking in the reviewed studies. Although the reviewed studies were of fairly high quality, we found Quality of Health Economic Studies methodology for grading the quality of economic evaluations challenging and observed no statistically significant improvement in quality of studies between the periods of 1995-2004 and 2004-2009.

Entities:  

Mesh:

Year:  2011        PMID: 21273949     DOI: 10.1097/GIM.0b013e3182003294

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  11 in total

Review 1.  Precision Medicine: From Science To Value.

Authors:  Geoffrey S Ginsburg; Kathryn A Phillips
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

Review 2.  Economics of stratified medicine in rheumatoid arthritis.

Authors:  Sean Gavan; Mark Harrison; Cynthia Iglesias; Anne Barton; Andrea Manca; Katherine Payne
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

3.  Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.

Authors:  Elizabeth J J Berm; Margot de Looff; Bob Wilffert; Cornelis Boersma; Lieven Annemans; Stefan Vegter; Job F M van Boven; Maarten J Postma
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

4.  A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.

Authors:  Dee Luo; James A Smith; Nick A Meadows; A Schuh; Katie E Manescu; Kim Bure; Benjamin Davies; Rob Horne; Mike Kope; David L DiGiusto; David A Brindley
Journal:  Front Genet       Date:  2016-01-28       Impact factor: 4.599

Review 5.  Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.

Authors:  Elvira D'Andrea; Carolina Marzuillo; Corrado De Vito; Marco Di Marco; Erica Pitini; Maria Rosaria Vacchio; Paolo Villari
Journal:  Genet Med       Date:  2016-04-14       Impact factor: 8.822

6.  The economic value of personalized medicine tests: what we know and what we need to know.

Authors:  Kathryn A Phillips; Julie Ann Sakowski; Julia Trosman; Michael P Douglas; Su-Ying Liang; Peter Neumann
Journal:  Genet Med       Date:  2013-10-17       Impact factor: 8.822

Review 7.  Issues surrounding the health economic evaluation of genomic technologies.

Authors:  James Buchanan; Sarah Wordsworth; Anna Schuh
Journal:  Pharmacogenomics       Date:  2013-11       Impact factor: 2.533

8.  Economic evaluation in psychiatric pharmacogenomics: a systematic review.

Authors:  Kariofyllis Karamperis; Maria Koromina; Panagiotis Papantoniou; Maria Skokou; Filippos Kanellakis; Konstantinos Mitropoulos; Athanassios Vozikis; Daniel J Müller; George P Patrinos; Christina Mitropoulou
Journal:  Pharmacogenomics J       Date:  2021-07-02       Impact factor: 3.550

Review 9.  Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations.

Authors:  Annamaria Guglielmo; Nicoletta Staropoli; Monica Giancotti; Marianna Mauro
Journal:  Cost Eff Resour Alloc       Date:  2018-01-22

10.  Concepts of 'personalization' in personalized medicine: implications for economic evaluation.

Authors:  Wolf Rogowski; Katherine Payne; Petra Schnell-Inderst; Andrea Manca; Ursula Rochau; Beate Jahn; Oguzhan Alagoz; Reiner Leidl; Uwe Siebert
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.